Why it is moving
The proposed policy could alter the regulatory and supply-chain environment in the biopharmaceutical industry, creating new barriers or opportunities for companies in this sector.
Driver data is partial
Some drivers have no confirmed source evidence yet, read those as context, not confirmation.
Main drivers
US Senate bill proposal aiming to reduce drug industry reliance on China.
No confirmed source evidence yet.
Upcoming events